RESEARCH ARTICLE


Understanding Beta-Thalassemia with Focus on the Indian Subcontinent and the Middle East



P. Lahiry§, S.A. Al-Attar§, R.A. Hegele *
Vascular Biology Research Group, Robarts Research Institute and the University of Western Ontario, Canada.

Article Information


Identifiers and Pagination:

Year: 2008
Volume: 2
First Page: 5
Last Page: 13
Publisher Id: TOHJ-2-5
DOI: 10.2174/1874276900802010005

Article History:

Received Date: 28/10/2007
Revision Received Date: 21/11/2007
Acceptance Date: 23/11/2007
Electronic publication date: 22/1/2008
Collection year: 2008

Article Metrics

CrossRef Citations:
12
Total Statistics:

Full-Text HTML Views: 392
Abstract HTML Views: 424
PDF Downloads: 0
Total Views/Downloads: 816
Unique Statistics:

Full-Text HTML Views: 248
Abstract HTML Views: 277
PDF Downloads: 0
Total Views/Downloads: 525



© 2008 Lahiry et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Vascular Biology Research Group, Robarts Research Institute and the University of Western Ontario, Canada; E-mail: hegele@robarts.ca
§ These authors contributed equally to this work


Abstract

Beta-thalassemia is one of the most prevalent autosomal disorders in the world. Mutations in the HBB gene underlie deficiencies in hemoglobin production, which can interfere with oxygen delivery resulting in wide range of disease severity. Although >535 mutations have been characterized in the HBB gene, beta-thalassemia is broadly classified into three groups, based on clinical severity: beta-thalassemia major, beta-thalassemia intermedia and beta-thalassemia minor. In this article we review: 1) the molecular and biochemical basis of beta-thalassemia; 2) clinical features; 3) the range of common molecular variants of beta-thalassemia in a subset of geographic regions within the Indian Subcontinent and the Middle East; 4) potential molecular diagnostics; and 5) current and future treatments. We suggest that efforts to more completely characterize the HBB mutation distribution in high-risk areas, such as the Indian Subcontinent and the Middle East, may lead to improved diagnosis with earlier and more effective intervention strategies.